STAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate at the Cowen 43rd Annual Healthcare Conference in Boston, MA. Katherine Stueland, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, March 7, 2023, at 2:50 p.m. ET.
A live and archived webcast of the presentation will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.
About GeneDx
GeneDx, (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest rare disease data sets.
For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
Investor contact
Tricia Truehart
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media contact
Stephanie Kahan
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$98.28 |
| Daily Change: | -3.94 -3.85 |
| Daily Volume: | 749,963 |
| Market Cap: | US$2.700B |
April 16, 2025 April 03, 2025 March 13, 2025 March 04, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
